Intracranial Metastasis of Soft Tissue Fibrosarcoma

Takamiya, Yoshiaki; Toya, Shigeo; Iizaka, Y.; Otani, Mitsuhiro; Takenaka, Nobuo; Imanishi, T.

doi:10.2176/nmc.26.54

Cited by 5 publications

(1 citation statement)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although these tumors can originate from either bone or soft tissue, defining the source is difficult [65]. Successful SR of the primary site with clear margins can be difficult; thus, local recurrence and metastasis are frequent.…”

Section: Resultsmentioning

confidence: 99%

Brain Metastasis in Bone and Soft Tissue Cancers: A Review of Incidence, Interventions, and Outcomes

Shweikeh

Bukavina

Saeed

et al. 2014

Sarcoma

View full text Add to dashboard Cite

Bone and soft tissue malignancies account for a small portion of brain metastases. In this review, we characterize their incidence, treatments, and prognosis. Most of the data in the literature is based on case reports and small case series. Less than 5% of brain metastases are from bone and soft tissue sarcomas, occurring most commonly in Ewing's sarcoma, malignant fibrous tumors, and osteosarcoma. Mean interval from initial cancer diagnosis to brain metastasis is in the range of 20–30 months, with most being detected before 24 months (osteosarcoma, Ewing sarcoma, chordoma, angiosarcoma, and rhabdomyosarcoma), some at 24–36 months (malignant fibrous tumors, malignant peripheral nerve sheath tumors, and alveolar soft part sarcoma), and a few after 36 months (chondrosarcoma and liposarcoma). Overall mean survival ranges between 7 and 16 months, with the majority surviving < 12 months (Ewing's sarcoma, liposarcoma, malignant fibrous tumors, malignant peripheral nerve sheath tumors, angiosarcoma and chordomas). Management is heterogeneous involving surgery, radiosurgery, radiotherapy, and chemotherapy. While a survival advantage may exist for those given aggressive treatment involving surgical resection, such patients tended to have a favorable preoperative performance status and minimal systemic disease.

show abstract

Section: Resultsmentioning

confidence: 99%